Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × Shock, Septic × Clear all

Phase

Phase 3 3 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 40 Neoplasms 36 Prostatic Neoplasms 32 Colorectal Neoplasms 22 Leukemia, Myeloid, Acute 21 Carcinoma, Non-Small-Cell Lung 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Neoplasm Metastasis 14 Lung Neoplasms 13 Stomach Neoplasms 12 Polycystic Ovary Syndrome 12 Multiple Myeloma 11 Carcinoma, Hepatocellular 11 Recurrence 10 Pancreatic Neoplasms 10 Urinary Bladder Neoplasms 9 Lymphoma 9 Leukemia 9 Myelodysplastic Syndromes 8 Motor Activity 8 Head and Neck Neoplasms 8 Liver Neoplasms 7 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7 Esophageal Neoplasms 7 Colonic Neoplasms 7 Brain Neoplasms 7 Pain 6 Ovarian Neoplasms 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6

Interventions

Saline Solution 1 Methylene Blue 1 Contraceptives, Oral 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06005558 2024-07-05

Low Dose Versus High Dose Methylene Blue in Septic Patients

National Cancer Institute, Egypt

Phase 2/3 Completed

Shock, Septic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡